Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis.

Ghafari N, Court R, Chirehwa MT, Wiesner L, Petersen L, Maartens G, Gumbo T, McIlleron H, Ramma L.

Int J Audiol. 2019 Nov 18:1-5. doi: 10.1080/14992027.2019.1690170. [Epub ahead of print]

PMID:
31739701
2.

Correction to: Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy.

Svensson EM, Yngman G, Denti P, McIlleron H, Kjellsson MC, Karlsson MO.

Clin Pharmacokinet. 2019 Nov 2. doi: 10.1007/s40262-019-00835-4. [Epub ahead of print]

PMID:
31677024
3.

Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis.

Court R, Chirehwa MT, Wiesner L, de Vries N, Harding J, Gumbo T, Maartens G, McIlleron H.

Int J Tuberc Lung Dis. 2019 Oct 1;23(10):1068-1074. doi: 10.5588/ijtld.18.0775.

PMID:
31627771
4.

Integrating pharmacokinetics and pharmacodynamics in operational research to End TB.

Alffenaar JC, Gumbo T, Dooley KE, Peloquin CA, McIlleron H, Zagorski A, Cirillo DM, Heysell SK, Silva DR, Migliori GB.

Clin Infect Dis. 2019 Sep 27. pii: ciz942. doi: 10.1093/cid/ciz942. [Epub ahead of print]

PMID:
31560376
5.

Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate (DMPA) in African women receiving treatment for HIV and TB: Potential concern for standard dosing frequency.

Mngqibisa R, Kendall MA, Dooley K, Wu X, Firnhaber C, McIlleron H, Robinson J, Cramer Y, Rosenkranz SL, Roa J, Coughlin K, Mawlana S, Badal-Faesen S, Schnabel D, Omoz-Oarhe A, Samaneka W, Godfrey C, Cohn SE; A5338 study team.

Clin Infect Dis. 2019 Sep 5. pii: ciz863. doi: 10.1093/cid/ciz863. [Epub ahead of print]

PMID:
31504342
6.

Quantitative assessment of the activity of antituberculosis drugs and regimens.

Chirehwa MT, Velásquez GE, Gumbo T, McIlleron H.

Expert Rev Anti Infect Ther. 2019 Jun;17(6):449-457. doi: 10.1080/14787210.2019.1621747. Epub 2019 May 30.

PMID:
31144539
7.

Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin.

Rabie H, Rawizza H, Zuidewind P, Winckler J, Zar H, Van Rie A, Wiesner L, McIlleron H.

J Antimicrob Chemother. 2019 Aug 1;74(8):2347-2351. doi: 10.1093/jac/dkz171.

PMID:
31081020
8.

Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.

Naidoo A, Chirehwa M, Ramsuran V, McIlleron H, Naidoo K, Yende-Zuma N, Singh R, Ncgapu S, Adamson J, Govender K, Denti P, Padayatchi N.

Pharmacogenomics. 2019 Mar;20(4):225-240. doi: 10.2217/pgs-2018-0166. Epub 2019 Feb 15.

PMID:
30767706
9.

A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine.

Francis J, Zvada SP, Denti P, Hatherill M, Charalambous S, Mungofa S, Dawson R, Dorman S, Gupte N, Wiesner L, Jindani A, Harrison TS, Olagunju A, Egan D, Owen A, McIlleron HM.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01964-18. doi: 10.1128/AAC.01964-18. Print 2019 Apr.

10.

Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical study.

Rabie H, Denti P, Lee J, Masango M, Coovadia A, Pillay S, Liberty A, Simon F, McIlleron H, Cotton MF, Lallemant M.

Lancet HIV. 2018 Dec 6. pii: S2352-3018(18)30293-5. doi: 10.1016/S2352-3018(18)30293-5. [Epub ahead of print]

PMID:
30529029
11.

Current research toward optimizing dosing of first-line antituberculosis treatment.

McIlleron H, Chirehwa MT.

Expert Rev Anti Infect Ther. 2019 Jan;17(1):27-38. doi: 10.1080/14787210.2019.1555031. Epub 2018 Dec 12. Review.

12.

Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.

Magombedze G, Pasipanodya JG, Srivastava S, Deshpande D, Visser ME, Chigutsa E, McIlleron H, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S349-S358. doi: 10.1093/cid/ciy623.

13.

d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

Deshpande D, Alffenaar JC, Köser CU, Dheda K, Chapagain ML, Simbar N, Schön T, Sturkenboom MGG, McIlleron H, Lee PS, Koeuth T, Mpagama SG, Banu S, Foongladda S, Ogarkov O, Pholwat S, Houpt ER, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S308-S316. doi: 10.1093/cid/ciy624.

14.

Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Srivastava S, Bendet P, Koeuth T, Bhavnani SM, Ambrose PG, Smythe W, McIlleron H, Thwaites G, Gumusboga M, Van Deun A, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S274-S283. doi: 10.1093/cid/ciy618.

PMID:
30496459
15.

Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.

Pasipanodya JG, Smythe W, Merle CS, Olliaro PL, Deshpande D, Magombedze G, McIlleron H, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S284-S292. doi: 10.1093/cid/ciy610.

PMID:
30496458
16.

A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs.

Daskapan A, Idrus LR, Postma MJ, Wilffert B, Kosterink JGW, Stienstra Y, Touw DJ, Andersen AB, Bekker A, Denti P, Hemanth Kumar AK, Jeremiah K, Kwara A, McIlleron H, Meintjes G, van Oosterhout JJ, Ramachandran G, Rockwood N, Wilkinson RJ, van der Werf TS, Alffenaar JC.

Clin Pharmacokinet. 2019 Jun;58(6):747-766. doi: 10.1007/s40262-018-0716-8. Review.

17.

Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol.

Myers B, Bouton TC, Ragan EJ, White LF, McIlleron H, Theron D, Parry CDH, Horsburgh CR, Warren RM, Jacobson KR.

BMC Infect Dis. 2018 Sep 29;18(1):488. doi: 10.1186/s12879-018-3396-y.

18.

Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.

Chirehwa MT, McIlleron H, Wiesner L, Affolabi D, Bah-Sow O, Merle C, Denti P; RAFA team.

J Antimicrob Chemother. 2019 Jan 1;74(1):139-148. doi: 10.1093/jac/dky378.

19.

Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis.

Court RG, Wiesner L, Chirehwa MT, Stewart A, de Vries N, Harding J, Gumbo T, McIlleron H, Maartens G.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):926-930. doi: 10.5588/ijtld.18.0091.

20.

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.

Stott KE, Pertinez H, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran G, Requena-Méndez A, Peloquin C, Koegelenberg CFN, Alffenaar JWC, Ruslami R, Tostmann A, Swaminathan S, McIlleron H, Davies G.

J Antimicrob Chemother. 2018 Sep 1;73(9):2305-2313. doi: 10.1093/jac/dky152.

21.

Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial.

Chabala C, Turkova A, Thomason MJ, Wobudeya E, Hissar S, Mave V, van der Zalm M, Palmer M, Kapasa M, Bhavani PK, Balaji S, Raichur PA, Demers AM, Hoddinott G, Owen-Powell E, Kinikar A, Musoke P, Mulenga V, Aarnoutse R, McIlleron H, Hesseling A, Crook AM, Cotton M, Gibb DM; SHINE trial team.

Trials. 2018 Apr 19;19(1):237. doi: 10.1186/s13063-018-2608-5.

22.

Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications.

Court R, Chirehwa MT, Wiesner L, Wright B, Smythe W, Kramer N, McIlleron H.

Int J Tuberc Lung Dis. 2018 May 1;22(5):537-543. doi: 10.5588/ijtld.17.0697.

23.

Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial.

Garcia-Prats AJ, Rose PC, Draper HR, Seddon JA, Norman J, McIlleron HM, Hesseling AC, Schaaf HS.

Pediatr Infect Dis J. 2018 Dec;37(12):1199-1203. doi: 10.1097/INF.0000000000001983.

24.

Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis.

Court R, Wiesner L, Stewart A, de Vries N, Harding J, Maartens G, Gumbo T, McIlleron H.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):30-33. doi: 10.5588/ijtld.17.0475.

25.

Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis.

Naidoo A, Ramsuran V, Chirehwa M, Denti P, McIlleron H, Naidoo K, Yende-Zuma N, Singh R, Ngcapu S, Chaudhry M, Pepper MS, Padayatchi N.

Pharmacogenomics. 2018 Jan;19(1):17-29. doi: 10.2217/pgs-2017-0144. Epub 2017 Dec 6.

26.

Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.

Denti P, Garcia-Prats AJ, Draper HR, Wiesner L, Winckler J, Thee S, Dooley KE, Savic RM, McIlleron HM, Schaaf HS, Hesseling AC.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01521-17. doi: 10.1128/AAC.01521-17. Print 2018 Feb.

27.

Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.

van der Laan LE, Garcia-Prats AJ, Schaaf HS, Tikiso T, Wiesner L, de Kock M, Winckler J, Norman J, McIlleron H, Denti P, Hesseling AC.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e00420-17. doi: 10.1128/AAC.00420-17. Print 2018 Feb.

28.

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy.

Svensson EM, Yngman G, Denti P, McIlleron H, Kjellsson MC, Karlsson MO.

Clin Pharmacokinet. 2018 May;57(5):591-599. doi: 10.1007/s40262-017-0577-6. Erratum in: Clin Pharmacokinet. 2019 Nov 2;:.

29.

A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.

Naidoo A, Naidoo K, McIlleron H, Essack S, Padayatchi N.

J Clin Pharmacol. 2017 Nov;57(11):1369-1386. doi: 10.1002/jcph.968. Epub 2017 Jul 24. Review.

30.

Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.

Chirehwa MT, McIlleron H, Rustomjee R, Mthiyane T, Onyebujoh P, Smith P, Denti P.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00490-17. doi: 10.1128/AAC.00490-17. Print 2017 Aug.

31.

Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis.

Olliaro PL, Merle C, Mthiyane T, Bah B, Kassa F, Amukoye E, N Diaye A, Perronne C, Lienhardt C, McIlleron H, Fielding K.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e01834-16. doi: 10.1128/AAC.01834-16. Print 2017 Jul.

32.

Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.

McIlleron H, Denti P, Cohn S, Mashabela F, Hoffmann JD, Shembe S, Msandiwa R, Wiesner L, Velaphi S, Lala SG, Chaisson RE, Martinson N, Dooley KE; Tshepiso Study Team.

J Antimicrob Chemother. 2017 Jul 1;72(7):2028-2034. doi: 10.1093/jac/dkx112.

33.

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30079-6. doi: 10.1016/S2213-2600(17)30079-6. [Epub ahead of print] Review.

PMID:
28344011
34.

Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.

Rockwood N, Pasipanodya JG, Denti P, Sirgel F, Lesosky M, Gumbo T, Meintjes G, McIlleron H, Wilkinson RJ.

Clin Infect Dis. 2017 May 15;64(10):1350-1359. doi: 10.1093/cid/cix158. Erratum in: Clin Infect Dis. 2017 Oct 15;65(8):1431-1433.

35.

Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.

Naidoo A, Chirehwa M, McIlleron H, Naidoo K, Essack S, Yende-Zuma N, Kimba-Phongi E, Adamson J, Govender K, Padayatchi N, Denti P.

J Antimicrob Chemother. 2017 May 1;72(5):1441-1449. doi: 10.1093/jac/dkx004.

36.

Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies.

Marais BJ, Heemskerk AD, Marais SS, van Crevel R, Rohlwink U, Caws M, Meintjes G, Misra UK, Mai NTH, Ruslami R, Seddon JA, Solomons R, van Toorn R, Figaji A, McIlleron H, Aarnoutse R, Schoeman JF, Wilkinson RJ, Thwaites GE; Tuberculous Meningitis International Research Consortium.

Clin Infect Dis. 2017 Feb 15;64(4):501-509. doi: 10.1093/cid/ciw757. Review.

37.

Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets.

Bienczak A, Denti P, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Gibb DM, Burger D, Walker AS, McIlleron H.

AIDS. 2017 Apr 24;31(7):905-915. doi: 10.1097/QAD.0000000000001376.

38.

Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients.

Bouazza N, Cressey TR, Foissac F, Bienczak A, Denti P, McIlleron H, Burger D, Penazzato M, Lallemant M, Capparelli EV, Treluyer JM, Urien S.

J Antimicrob Chemother. 2017 Feb;72(2):490-495. doi: 10.1093/jac/dkw444. Epub 2016 Oct 24.

PMID:
27798221
39.

Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.

Bienczak A, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Walker AS, Owen A, Gibb DM, Burger D, McIlleron H, Denti P.

J Antimicrob Chemother. 2017 Jan;72(1):190-199. Epub 2016 Oct 5.

40.

Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children.

Moholisa RR, Schomaker M, Kuhn L, Castel S, Wiesner L, Coovadia A, Strehlau R, Patel F, Pinillos F, Abrams EJ, Maartens G, McIlleron H.

Pediatr Infect Dis J. 2016 Dec;35(12):e378-e383.

41.

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.

Rockwood N, Meintjes G, Chirehwa M, Wiesner L, McIlleron H, Wilkinson RJ, Denti P.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6050-9. doi: 10.1128/AAC.00480-16. Print 2016 Oct.

42.

Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes.

McIlleron H, Hundt H, Smythe W, Bekker A, Winckler J, van der Laan L, Smith P, Zar HJ, Hesseling AC, Maartens G, Wiesner L, van Rie A.

Int J Tuberc Lung Dis. 2016 Jul;20(7):915-9. doi: 10.5588/ijtld.15.0833.

43.

Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.

Bienczak A, Denti P, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Gibb DM, Burger D, Walker AS, McIlleron H.

J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):161-8. doi: 10.1097/QAI.0000000000001032.

44.

Erratum for Chirehwa et al., Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.

Chirehwa MT, Rustomjee R, Mthiyane T, Onyebujoh P, Smith P, McIlleron H, Denti P.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3262. doi: 10.1128/AAC.00483-16. Print 2016 May. No abstract available.

45.

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.

Bienczak A, Cook A, Wiesner L, Olagunju A, Mulenga V, Kityo C, Kekitiinwa A, Owen A, Walker AS, Gibb DM, McIlleron H, Burger D, Denti P.

Br J Clin Pharmacol. 2016 Jul;82(1):185-98. doi: 10.1111/bcp.12934. Epub 2016 Apr 25.

46.

Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis.

Shenje J, Ifeoma Adimora-Nweke F, Ross IL, Ntsekhe M, Wiesner L, Deffur A, McIlleron HM, Pasipanodya J, Gumbo T, Mayosi BM.

EBioMedicine. 2015 Sep 16;2(11):1640-9. doi: 10.1016/j.ebiom.2015.09.025. eCollection 2015 Nov.

47.

Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.

Hennig S, Svensson EM, Niebecker R, Fourie PB, Weiner MH, Bonora S, Peloquin CA, Gallicano K, Flexner C, Pym A, Vis P, Olliaro PL, McIlleron H, Karlsson MO.

J Antimicrob Chemother. 2016 May;71(5):1330-40. doi: 10.1093/jac/dkv470. Epub 2016 Jan 31.

48.

Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.

Bekker A, Schaaf HS, Draper HR, van der Laan L, Murray S, Wiesner L, Donald PR, McIlleron HM, Hesseling AC.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2171-9. doi: 10.1128/AAC.02600-15. Print 2016 Apr.

49.

Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations.

Sinxadi PZ, McIlleron HM, Dave JA, Smith PJ, Levitt NS, Haas DW, Maartens G.

Medicine (Baltimore). 2016 Jan;95(2):e2385. doi: 10.1097/MD.0000000000002385.

50.

Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.

Pandie M, Wiesner L, McIlleron H, Hughes J, Siwendu S, Conradie F, Variava E, Maartens G.

J Antimicrob Chemother. 2016 Apr;71(4):1037-40. doi: 10.1093/jac/dkv447. Epub 2016 Jan 7.

PMID:
26747099

Supplemental Content

Loading ...
Support Center